TMEM200A, a transmembrane protein, has been associated with various biological processes and diseases. While its exact normal function remains to be fully elucidated, studies suggest it may play a role in processes related to cell adhesion, as co-expressed genes and gene set enrichment analysis indicated it could be an adhesion molecule [3,7]. It has also been linked to pathways such as the PI3K/AKT signaling pathway [1]. Its biological importance lies in its potential influence on cancer development and immune infiltration.

In gastric cancer, multiple studies have demonstrated significant associations. Knockdown of TMEM200A in gastric cancer cell lines inhibited cell proliferation, decreased vimentin, N-cadherin, and Snai proteins, and inhibited AKT phosphorylation, suggesting its role in the regulation of gastric cancer development through the PI3K/AKT signaling pathway and epithelial-mesenchymal transition (EMT) [1]. High expression of TMEM200A in gastric cancer tissues was associated with poor prognosis, and it was identified as an independent risk factor for overall survival. It also correlated with immune cell infiltration, with CD8+ T cells decreased and eosinophils increased in the high-expression group [2,3]. Additionally, in a study on a carboplatin-resistant ovarian cancer cell model, TMEM200A was potentially involved in both drug resistance and drug-induced EMT, having high predictive and prognostic values for ovarian cancer patients [6]. In the context of adipose morphology, siRNA-mediated knockdown in adipose-derived precursor cells suggested a regulatory role for TMEM200A in adipocyte renewal and differentiation [4]. In acute myeloid leukemia, TMEM200A was among the genes used to construct a risk-score model for predicting patient prognosis [5]. In stomach adenocarcinoma and precursor lesions in familial pancreatic cancer, TMEM200A was differentially expressed and potentially had prognostic value [7,8].

In conclusion, TMEM200A appears to be involved in diverse biological processes, with its role most extensively studied in cancer. High expression of TMEM200A in gastric cancer is associated with poor prognosis and immune infiltration, and it may regulate cancer development through the PI3K/AKT pathway and EMT. In other contexts, it may contribute to adipose morphology, drug resistance in ovarian cancer, and prognosis prediction in acute myeloid leukemia. The study of TMEM200A provides insights into disease mechanisms and potential biomarker discovery [1-8].

References:

1. Zhang, Yaowen, Kuang, Shanshan, Qin, Hancheng, Yang, Yixin, Xie, Jisheng. 2023. Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker. In Journal of visualized experiments : JoVE, , . doi:10.3791/65795. https://pubmed.ncbi.nlm.nih.gov/37782103/

2. Fang, Fujin, Zhang, Tiantian, Lei, Huan, Shen, Xiaobing. 2023. TMEM200A is a potential prognostic biomarker and correlated with immune infiltrates in gastric cancer. In PeerJ, 11, e15613. doi:10.7717/peerj.15613. https://pubmed.ncbi.nlm.nih.gov/37404478/

3. Deng, Hongyang, Li, Tengfei, Wei, Fengxian, Xu, Xiaodong, Zhang, Youcheng. 2023. High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer. In Pathology oncology research : POR, 29, 1610893. doi:10.3389/pore.2023.1610893. https://pubmed.ncbi.nlm.nih.gov/36741965/

4. Lundbäck, Veroniqa, Kulyté, Agné, Arner, Peter, Strawbridge, Rona J, Dahlman, Ingrid. 2020. Genome-Wide Association Study of Diabetogenic Adipose Morphology in the GENetics of Adipocyte Lipolysis (GENiAL) Cohort. In Cells, 9, . doi:10.3390/cells9051085. https://pubmed.ncbi.nlm.nih.gov/32349335/

5. Nie, Lirong, Zhang, Yuming, You, Yuchan, Luo, Wenying, He, Honghua. . The signature based on seven genomic instability-related genes could predict the prognosis of acute myeloid leukemia patients. In Hematology (Amsterdam, Netherlands), 27, 840-848. doi:10.1080/16078454.2022.2107970. https://pubmed.ncbi.nlm.nih.gov/35924822/

6. Kralj, Juran, Pernar Kovač, Margareta, Dabelić, Sanja, Köhrer, Karl, Brozovic, Anamaria. 2023. Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT. In British journal of cancer, 128, 1344-1359. doi:10.1038/s41416-023-02140-1. https://pubmed.ncbi.nlm.nih.gov/36717670/

7. Zhang, Xiulei, Zheng, Peiming, Li, Zhen, Gao, Shanjun, Liu, Guangzhi. 2020. The Somatic Mutation Landscape and RNA Prognostic Markers in Stomach Adenocarcinoma. In OncoTargets and therapy, 13, 7735-7746. doi:10.2147/OTT.S263733. https://pubmed.ncbi.nlm.nih.gov/32801780/

8. Tan, Ming, Schaffalitzky de Muckadell, Ove B, Jøergensen, Maiken Thyregod. 2020. Gene Expression Network Analysis of Precursor Lesions in Familial Pancreatic Cancer. In Journal of pancreatic cancer, 6, 73-84. doi:10.1089/pancan.2020.0007. https://pubmed.ncbi.nlm.nih.gov/32783019/